Pharmaceuticals

Ascletis (1672.HK) Included in the Hang Seng Hong Kong-Listed Biotech Index

HANGZHOU and SHAOXING, China, Feb. 27, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it will be included in the Hang Seng Hong Kong-Listed Biotech Index (Index code: HSHKBIO), effective from March 13, 2023. HSHKBIO selects securities of multiple listed co...

2023-02-27 17:15 4589

Turacoz Paves the Way in Digital Content Management for Healthcare Communications with Veeva & Expert Training

UTRECHT, Netherlands and NEW DELHI, Feb. 27, 2023 /PRNewswire/ -- As digital content gains importance in healthcare, the medical writing industry is transitioning to digital content management. Turacoz is setting the standar...

2023-02-27 17:07 2397

Telix 2022 Full Year Results: Revenue up 20x in first year of commercial sales, underpins transition to cash flow positive

MELBOURNE, Australia, Feb. 27, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the financial year ended31 December 2022. All figures are in AU$ unless otherwise stated. 2022 HIGHLIGHTS * Total Group revenue $160.1M ...

2023-02-27 14:37 2935

Servier receives a positive CHMP opinion for Tibsovo® in IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma (CCA) patients

* Tibsovo® (ivosidenib tablets) is the first IDH1 inhibitor recommended for approval inEurope * The positive CHMP opinion is based on clinical data from the AGILE (in AML) and ClarIDHy (in CCA) studies PARIS, Feb. 24, 2023 /PRNewswire/ -- Servier, a global pharmaceutical company, today announ...

2023-02-24 21:29 3428

HAVAS HEALTH & YOU AND THE AMERICAN PARKINSON DISEASE ASSOCIATION LAUNCH SEXUAL WELLNESS CAMPAIGN PARKINSEX

Activation Advances Nonclinical Strategies for People with Parkinson's to Deepen Intimacy NEW YORK, Feb. 23, 2023 /PRNewswire/ -- Parkinson's disease affects more than ten million people worldwide and the prevalence of sexual dysfunction is disproportionately high in patients, causing partners t...

2023-02-23 22:15 3004

TB Alliance Announces David Norton as Board Chair

NEW YORK, Feb. 23, 2023 /PRNewswire/ -- The TB Alliance Board of Directors has electedDavid Norton as Chairperson of the Board. In this role, David will provide leadership to a diverse Board committed to advancing the vision of TB Alliance. "David Norton has contributed greatly to TB Alliance's ...

2023-02-23 22:00 2952

Invivoscribe Diagnostic Technologies (Shanghai) Co. Ltd. Receives CAP Accreditation to Support Clinical Research Testing for Pharmaceutical Partners in China

SAN DIEGO, Feb. 23, 2023 /PRNewswire/ -- Today, Invivoscribe announced that its Shanghai lab in China has received CAP accreditation. The College of American Pathologists (CAP) is a professional organization that accredits clinical laboratories across the world. The CAP accreditation process is ...

2023-02-23 22:00 3734

Xspray Pharma Partners with EVERSANA® for the U.S. Launch and Commercialization of its Lead Product, Dasynoc (XS004) for the Treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphatic Leukemia (ALL)

STOCKHOLM, Feb. 23, 2023 /PRNewswire/ -- Xspray Pharma AB, (NASDAQ Stockholm: XSPRAY) has signed an agreement with EVERSANA® to support the U.S. launch and commercialization of the company's first innovative cancer therapy Dasynoc for the treatment of chronic myeloid leukemia (CML) and acute lymp...

2023-02-23 15:02 2391

Lepu Biopharma and Keymed Jointly Announces Global Exclusive Licence Agreement with AstraZeneca for CMG901

HONG KONG, Feb. 22, 2023 /PRNewswire/ -- Lepu Biopharma Co., Ltd. (Stock Code: 02157.HK) and Keymed Biosciences Inc., ("Keymed") (Stock Code: 02162 HK) today jointly announces a global exclusive licence agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for CMG901, a potential first-in-class Claudi...

2023-02-23 12:26 3505

Dawn Health partners with leading pharmaceutical company to transform chronic care

COPENHAGEN, Denmark, Feb. 23, 2023 /PRNewswire/ -- Dawn Health, a global leader in digital health, today announced a strategic partnership with Novartis, one of the leading medicines companies in the world, to support the development of a platform that enables the effective remote monitoring and ...

2023-02-23 12:16 2144

Ajinomoto Bio-Pharma Services Successfully Develops Highly Functional Ancestral RNA Ligase

TOKYO, Feb. 22, 2023 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce the development of a new enzyme for double strand oligonucleotide formation with high productivity...

2023-02-22 21:05 3616

CRT 2023 selects Syntach Cardiac Support System for Best Innovation Competition

LUND, Sweden, Feb. 22, 2023 /PRNewswire/ -- Syntach AB ("Syntach") is pleased to announce that the Company's Syntach Cardiac Support system (Syntach CS) has been selected for an oral presentation in the Best Innovation Competition to be held during the CRT 2023 annual meeting taking place at the ...

2023-02-22 20:22 3427

Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy

– Based on Results from Phase 3 BOSTON Study, Marketing Authorization Expands Multiple Myeloma Indication – NEWTON, Mass. and FLORENCE, Italy, Feb. 21, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, an...

2023-02-21 23:04 4195

New Study Shows GlycoMark® Test Identifies Prediabetic Individuals with the Highest Risk of Developing Diabetes Before Symptoms Develop

RALEIGH, N.C., Feb. 21, 2023 /PRNewswire/ -- A new study indicates that the GlycoMark blood test identifies high-risk, asymptomatic patients with prediabetes, not detected by standard diabetes tests, hemoglobin A1C and glucose  – a critical clinical need, as physicians can identify those patients...

2023-02-21 20:30 2434

Synbio Tech Inc. and Cosmax Group signed an exclusive cooperation agreement to jointly expand the South Korean probiotics market

KAOHSIUNG, Taiwan, Feb. 21, 2023 /PRNewswire/ -- Synbio Tech Inc. and Cosmax NBT, a major South Korean biotechnology company officially signed an exclusive cooperation agreement to launchLactobacillus plantarum TWK10® probiotic strain inSouth Korea, and announced that TWK10® has been approved as ...

2023-02-21 16:01 5065

Nippon Express Singapore Receives IATA CEIV Pharma Certification for Changi International Airport Facility

TOKYO, Feb. 21, 2023 /PRNewswire/ -- Nippon Express (Singapore) Pte. Ltd. (hereinafter "NX Singapore"), a group company of NIPPON EXPRESS HOLDINGS, INC., has acquired IATA CEIV Pharma (*) certification for its facility in the Free Trade Zone (FTZ) at Singapore Changi International Airport, effect...

2023-02-21 14:00 3407

Pharming announces first patient enrolled in pediatric clinical trial of leniolisib

The multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency LEIDEN, Netherlands, Feb. 21, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM)/(Nasdaq: PHAR) announces t...

2023-02-21 14:00 4797

Ascletis Presented Positive Phase I Clinical Data for Broad-Spectrum Antiviral Double Prodrug ASC10 at CROI 2023

--At the dosage of 800 mg ASC10, twice daily (BID), the exposure of the active drug, ASC10-A, is comparable to that of monupiravir's --ASC10 at 800 mg, BID is safe and well tolerated --Dosage of 800 mg ASC10, BID was selected for Phase IIa clinical trial for respiratory syncytial virus (RSV) inf...

2023-02-21 08:10 3969

Significant Progress Made on the Trivalent Recombinant Protein COVID-19 Vaccine against Subvariants including XBB.1.5 and BA.5 by WestVac Biopharma

CHENGDU, China, Feb. 20, 2023 /PRNewswire/ -- Recently, with the support of the National Key R&D Program ofChina, following the clinical trial approval for Recombinant Variant COVID-19 Vaccine (Sf9 cell) approved by NMPA, WestVac Biopharma (Guangzhou) Co., Ltd. (hereinafter referred to as "WestVa...

2023-02-20 12:43 4636

Detailed Results from Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented at ASCO GU

Trial met primary and secondary endpoints and confirmed favourable safety and tolerability profile, indicating TLX250-CDx has the potential to become a new clinical standard in the identification and characterisation of clear cell renal cell carcinoma (ccRCC): * Primary endpoint met: Sensitivi...

2023-02-20 07:10 3385
1 ... 119120121122123124125 ... 184